Today we get an update on where the TB Vaccine pipeline is up to, how TB vaccines work and what exciting candidates might be on the horizon. We speak with Professor Jamie Triccas from the University of Sydney about his work as the principal investigator on the Advancing Vaccine Adjuvant Research for Tuberculosis (AVAR-T) which is an NIH funded project to identify the most promising adjuvant-TB immunogenicity candidates for development.
REFERENCES
Stewart, Erica, James A. Triccas, and Nikolai Petrovsky. "Adjuvant strategies for more effective tuberculosis vaccine immunity." Microorganisms 7.8 (2019): 255.
Counoupas, Claudio, James A. Triccas, and Warwick J. Britton. "Deciphering protective immunity against tuberculosis: implications for vaccine development." Expert Review of Vaccines 18.4 (2019): 353-364.
Triccas, James A., and Jonathan K. Nambiar. "Challenge of developing new tuberculosis vaccines to generate life-long protective immunity." Expert Review of Vaccines 8.7 (2009): 823-825.
Counoupas, Claudio, et al. "Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis." npj Vaccines 5.1 (2020): 105.
Counoupas, Claudio, and James A. Triccas. "The generation of T‐cell memory to protect against tuberculosis." Immunology and Cell Biology 97.7 (2019): 656-663.
Triccas, James A., and Claudio Counoupas. "Novel vaccination approaches to prevent tuberculosis in children." Pneumonia 8 (2016): 1-7.
Counoupas, Claudio, et al. "Protective efficacy of recombinant BCG over-expressing protective, stage-specific antigens of Mycobacterium tuberculosis." Vaccine 36.19 (2018): 2619-2629.
Counoupas, Claudio, et al. "Mycobacterium tuberculosis components expressed during chronic infection of the lung contribute to long-term control of pulmonary tuberculosis in mice." npj Vaccines 1.1 (2016): 1-11.
Today we get an update on where the TB Vaccine pipeline is up to, how TB vaccines work and what exciting candidates might be on the horizon. We speak with Professor Jamie Triccas from the University of Sydney about his work as the principal investigator on the Advancing Vaccine Adjuvant Research for Tuberculosis (AVAR-T) which is an NIH funded project to identify the most promising adjuvant-TB immunogenicity candidates for development.
REFERENCES
Stewart, Erica, James A. Triccas, and Nikolai Petrovsky. "Adjuvant strategies for more effective tuberculosis vaccine immunity." Microorganisms 7.8 (2019): 255.
Counoupas, Claudio, James A. Triccas, and Warwick J. Britton. "Deciphering protective immunity against tuberculosis: implications for vaccine development." Expert Review of Vaccines 18.4 (2019): 353-364.
Triccas, James A., and Jonathan K. Nambiar. "Challenge of developing new tuberculosis vaccines to generate life-long protective immunity." Expert Review of Vaccines 8.7 (2009): 823-825.
Counoupas, Claudio, et al. "Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis." npj Vaccines 5.1 (2020): 105.
Counoupas, Claudio, and James A. Triccas. "The generation of T‐cell memory to protect against tuberculosis." Immunology and Cell Biology 97.7 (2019): 656-663.
Triccas, James A., and Claudio Counoupas. "Novel vaccination approaches to prevent tuberculosis in children." Pneumonia 8 (2016): 1-7.
Counoupas, Claudio, et al. "Protective efficacy of recombinant BCG over-expressing protective, stage-specific antigens of Mycobacterium tuberculosis." Vaccine 36.19 (2018): 2619-2629.
Counoupas, Claudio, et al. "Mycobacterium tuberculosis components expressed during chronic infection of the lung contribute to long-term control of pulmonary tuberculosis in mice." npj Vaccines 1.1 (2016): 1-11.